Clinical experience with the treatment of hepatitis C infection in patients on opioid pharmacotherapy

Addiction

Volumn 106, Issue 5, 2011, Pages 977-984

  Sasadeusz, Joseph John ^a   Dore, Gregory ^b   Kronborg, Ian ^c   Barton, David ^d   Yoshihara, Motoko ^e   Weltman, Martin ^f  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c WESTERN HOSPITAL   (Australia)

^d MONASH UNIVERSITY   (Australia)

^e Roche Products   (Australia)

^f NEPEAN HOSPITAL   (Australia)

Author keywords

Depression; Hepatitis; Injecting drug use; Pegylated interferon; Ribavirin; Therapy opioid pharmacotherapy

Indexed keywords

ALPHA2A INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; NARCOTIC ANALGESIC AGENT; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; AUSTRALIA; CLINICAL TRIAL; DRUG COMBINATION; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; ISOLATION AND PURIFICATION; MAJOR DEPRESSION; MALE; METHODOLOGY; MULTICENTER STUDY; OPIATE SUBSTITUTION TREATMENT; PATIENT COMPLIANCE; PSYCHOLOGICAL ASPECT; STATISTICS; SUBSTANCE ABUSE; TREATMENT OUTCOME; VIROLOGY;

ADULT; ANALGESICS, OPIOID; ANTIVIRAL AGENTS; AUSTRALIA; DEPRESSIVE DISORDER, MAJOR; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MEDICATION ADHERENCE; OPIATE SUBSTITUTION TREATMENT; POLYETHYLENE GLYCOLS; RIBAVIRIN; RNA, VIRAL; SUBSTANCE ABUSE DETECTION; SUBSTANCE ABUSE, INTRAVENOUS; TREATMENT OUTCOME;

EID: 79953772327     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2010.03347.x     Document Type: Article

References (27)

1. Lauer G., Walker B. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52.
2. World Health Organization (WHO). World Health Report 2002. Annex Table 2: Deaths by Cause, Sex and Mortality Stratum in WHO Regions, Estimates for 2001. Geneva: WHO; 2001.
3. National Centre in HIV Epidemiology and Clinical Research (NCHECR). Hepatitis C Virus Projections Working Group. Estimates and Projections of the Hepatitis C Virus Epidemic in Australia. Sydney: NCHECR; 2002.
4. Micallef J. M., Kaldor J. M., Dore G. J. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 2006; 13: 34-41.
5. Poynard T., Yuen M.-F., Ratziu V., Lai C. Viral hepatitis C. Lancet 2003; 362: 2095-100.
6. Manns M., McHutchison J., Gordon S., Rustgi V., Shiffman M., Reindollar R. etal. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
7. Fried M., Shiffman M., Reddy K., Smith C., Marinos G., Goncales F. J. etal. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
8. Hadziyannis S., Sette H. J., Morgan T., Balan V., Diago M., Marcellin P. etal. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.
9. Ferenci P., Staufer K. Depression in chronic hepatitis: the virus, the drug, or the ethnic background?. Liver Int 2008; 28: 429-31.
10. McHutchison J. G., Manns M., Patel K., Poynard T., Lindsay K. L., Trepo C. etal. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061-9.
11. Beck A., Ward C., Mendelson M., Mock J., Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561-71.
12. Sheehan D., Lecrubier Y., Sheehan K., Amorim P., Janavs J., Weiller E. etal. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59: 2233.
13. Schaefer M., Schmidt F., Folwaczny C., Lorenz R., Martin G., Schindlbeck N. etal. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003; 37: 447-51.
14. Backmund M., Meyer K., Von Zielonka M., Eichenlaub D. Treatment of hepatitis C infection in injection drug users Markus Backmund. Hepatology 2001; 34: 188-93.
15. Sylvestre D. Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Depend 2002; 67: 117-23.
16. Van Theil D., Anantharaju A., Creech S. Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse. Am J Gastroenterol 2003; 98: 2281-8.
17. Mauss S., Berger F., Goelz J., Jacob B., Schmutz G. H. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology 2004; 40: 120-4.
18. Dore G. J., Law M., MacDonald M., Kaldor J. M. Epidemiology of hepatitis C virus infection in Australia. J Clin Virol 2003; 26: 171-84.
19. Robaeys G., Van Vlierberghe H., Mathei C., Van Ranst M., Bruckers L., Buntinx F. etal. Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes [see comment]. Gastroenterology 2006; 18: 159-6.
20. Grebely J., Raffa J. D., Meagher C., Duncan F., Genoway K. A., Khara M. etal. Directly observed therapy for the treatment of hepatitis C virus infection in current and former injection drug users. J Gastroenterol Hepatol 2007; 22: 1519-25.
21. Breschkin A., Siebert D., Locarnini S., Bowden S. Hepatitis C: laboratory diagnosis and monitoring. In: Kellerman G. K., editor. Abnormal Laboratory Results. Sydney: McGraw Hill; 2006, p. 247-61.
22. Anonymous. Consensus Development Statement. Mangmement of Hepatitis C: 2002. Bethesda: National Institutes of Health; 2002.
23. Dalgard O., Bjoro K., Hellum K., Myrvang B., Skaug K., Gutigard B. etal. Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up. Eur Addict Res 2002; 8: 45-9.
24. Mehta S., Cox A., Hoover D., Wang X.-H., Mao Q., Ray S. etal. Protection against persistence of hepatitis C. Lancet 2002; 359: 1478-83.
25. Li Y., Zhang T., Douglas S. D., Lai J. P., Xiao W. D., Pleasure D. E. etal. Morphine enhances hepatitis C virus (HCV) replicon expression. Am J Pathol 2003; 163: 1167-75.
26. National Centre in HIV Epidemiology and Clinical Research (NCHECR). HIV/AIDS, Viral Hepatitis and Sexually Transmissible Infections in Australia. Annual Surveillance Report 2002. Sydney: National Centre in HIV Epidemiology and Clinical Research (NCHECR); 2002.
27. Doab A., Treloar C., Dore G. J. Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia. Clin Infect Dis 2005; 40: S313-320.